Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathilda Mandel

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of Neurology|March 2, 2022
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimodAnat Achiron, Mathilda Mandel, Michael Gurevich, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Immunologic Research|April 13, 2013
Evaluation of an automated chemiluminescent immunoassay kit for antinuclear antibodies in autoimmune diseasesYaron Zafrir, Boris Gilburd, Marina Garcia Carrasco, et al.
Multiple Sclerosis and Related Disorders|March 18, 2023
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumabAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of Neuroimmunology|October 16, 2021
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional studyAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of the Neurological Sciences|January 29, 2022
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster doseSapir Dreyer-Alster, Shay Menascu, Mathilda Mandel, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of Neurology|March 2, 2022
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimodAnat Achiron, Mathilda Mandel, Michael Gurevich, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Immunologic Research|April 13, 2013
Evaluation of an automated chemiluminescent immunoassay kit for antinuclear antibodies in autoimmune diseasesYaron Zafrir, Boris Gilburd, Marina Garcia Carrasco, et al.
Multiple Sclerosis and Related Disorders|March 18, 2023
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumabAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of Neuroimmunology|October 16, 2021
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional studyAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of the Neurological Sciences|January 29, 2022
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster doseSapir Dreyer-Alster, Shay Menascu, Mathilda Mandel, et al.
Pageof 4